Glaukos Corporation GKOS
Updated: 9 Sep 2026
No signal published yet
We already track Glaukos and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Glaukos Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Glaukos free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 29, 2026, Glaukos reported second-quarter 2026 financial results, achieving net sales of $185.6 million, up 50% year-over-year. Top-line growth was primarily driven by strong commercial adoption of iDose TR and Epioxa. Following the performance, the company raised its full-year 2026 net sales guidance to a range of $680 million to $700 million.
What Firelda Watch includes for Glaukos Corporation
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Glaukos Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Glaukos free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more